Research programme: malaria vaccine - GeoVax Labs

Drug Profile

Research programme: malaria vaccine - GeoVax Labs

Latest Information Update: 02 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GeoVax Labs
  • Developer Burnet Institute; GeoVax Labs
  • Class Parasitic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Malaria

Most Recent Events

  • 18 Jan 2017 Preclinical trials in Malaria (Prevention) in USA (Parenteral) before January 2017 (Geovax Labs pipeline, January 2017)
  • 09 Jan 2017 Geovax Labs and Burnet Institute agree to co-develop malaria vaccine in USA for prevention of Malaria
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top